Forest Laboratories (FRX) 93.49 $FRX
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in Connection with the Proposed Sale of the Company to Forest Laboratories, Inc.
Business Wire - Mon May 05, 3:41PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) and other violations of state law by the board of directors of Furiex relating to the proposed buyout of the Company by Forest Laboratories, Inc. ("Forest" .
Commit To Buy Forest Laboratories At $87.50, Earn 8.3% Annualized Using Options
at The Street - Mon May 05, 10:36AM CDT
Investors eyeing a purchase of Forest Laboratories, Inc. stock, but tentative about paying the going market price of $92.24/share, might benefit from considering selling puts among the alternative strategies at their disposal.
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Mon May 05, 9:39AM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.
Former Forest Laboratories GC Joins Lowenstein Sandler's Life Sciences Practice
PR Newswire - Mon May 05, 9:00AM CDT
Herschel S. Weinstein joined Lowenstein Sandler LLP today as Senior Counsel and Vice-Chair of its Life Sciences Group. Mr. Weinstein has more than 30 years of experience as in-house and outside counsel to the pharmaceutical industry. He most recently served as Senior Vice President and General Counsel at Forest Laboratories, the New York Stock Exchange listed specialty pharmaceutical company with more than $4 billion in annual revenue. Mr. Weinstein will be resident in Lowenstein's New York office.
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC" by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm.
Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), WellPoint Inc. (NYSE: WLP), UnitedHealth Group Inc. (NYSE: UNH), Forest Laboratories Inc. (NYSE: FRX) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2020-100free.
Forest Laboratories, Inc. to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting
Business Wire - Fri May 02, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the American Psychiatric Association (APA) 167th annual meeting (May 3-7, 2014 in New York, N.Y.).
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc.
Business Wire - Fri May 02, 10:21AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) ("Furiex" in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" .
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc. Buyout
Business Wire - Thu May 01, 2:37PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (Nasdaq:FURX) relating to the proposed acquisition by Forest Laboratories, Inc.
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week(R) 2014
Business Wire - Thu May 01, 7:31AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week(R) 2014 in Chicago, May 3 through May 6, 2014. The data will be presented through the following poster presentations:
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Actavis Tops Q1 Earnings & Sales Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:25PM CDT
Actavis (ACT), which will be acquiring Forest Labs in mid-14, will provide updated guidance once the acquisition goes through.
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc. -- FURX
PR Newswire - Wed Apr 30, 1:41PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS: FURX) ("Furiex" in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" .
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped...
Next Resistance Level for Forest Laboratories (FRX) is $91.80
Comtex SmarTrend(R) - Wed Apr 30, 9:32AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $89.76 today and have reached the first resistance level of $90.76. Should the shares continue to rise, the resistance pivots of $91.80 and $93.84 will be of interest.
Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate, an Industrial Info News Alert
Marketwire - Wed Apr 30, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE
FE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England).
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in Connection with the Proposed Sale of the Company to Forest Laboratories, Inc.
Business Wire - Mon May 05, 3:41PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) and other violations of state law by the board of directors of Furiex relating to the proposed buyout of the Company by Forest Laboratories, Inc. ("Forest" . Commit To Buy Forest Laboratories At $87.50, Earn 8.3% Annualized Using Options
at The Street - Mon May 05, 10:36AM CDT
Investors eyeing a purchase of Forest Laboratories, Inc. stock, but tentative about paying the going market price of $92.24/share, might benefit from considering selling puts among the alternative strategies at their disposal.
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Mon May 05, 9:39AM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
(Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court. Former Forest Laboratories GC Joins Lowenstein Sandler's Life Sciences Practice
PR Newswire - Mon May 05, 9:00AM CDT
Herschel S. Weinstein joined Lowenstein Sandler LLP today as Senior Counsel and Vice-Chair of its Life Sciences Group. Mr. Weinstein has more than 30 years of experience as in-house and outside counsel to the pharmaceutical industry. He most recently served as Senior Vice President and General Counsel at Forest Laboratories, the New York Stock Exchange listed specialty pharmaceutical company with more than $4 billion in annual revenue. Mr. Weinstein will be resident in Lowenstein's New York office.
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm. Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), WellPoint Inc. (NYSE: WLP), UnitedHealth Group Inc. (NYSE: UNH), Forest Laboratories Inc. (NYSE: FRX) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2020-100free.
Forest Laboratories, Inc. to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting
Business Wire - Fri May 02, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the American Psychiatric Association (APA) 167th annual meeting (May 3-7, 2014 in New York, N.Y.).
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc.
Business Wire - Fri May 02, 10:21AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) ("Furiex"
in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc. Buyout
Business Wire - Thu May 01, 2:37PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(Nasdaq:FURX) relating to the proposed acquisition by Forest Laboratories, Inc. Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week(R) 2014
Business Wire - Thu May 01, 7:31AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week(R) 2014 in Chicago, May 3 through May 6, 2014. The data will be presented through the following poster presentations:
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Actavis Tops Q1 Earnings & Sales Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:25PM CDT
Actavis (ACT), which will be acquiring Forest Labs in mid-14, will provide updated guidance once the acquisition goes through.
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc. -- FURX
PR Newswire - Wed Apr 30, 1:41PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS: FURX) ("Furiex"
in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped...
Next Resistance Level for Forest Laboratories (FRX) is $91.80
Comtex SmarTrend(R) - Wed Apr 30, 9:32AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $89.76 today and have reached the first resistance level of $90.76. Should the shares continue to rise, the resistance pivots of $91.80 and $93.84 will be of interest.
Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate, an Industrial Info News Alert
Marketwire - Wed Apr 30, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE
FE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England). 
